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1. Introduction 
From ancient times, medicinal plants have played an important role in the treatment of 
diseases, especially in those related with the central nervous system (CNS). The study of 
opium properties (Papaver somniferum), marijuana (Cannabis sativa L.), mandragora 
(Mandragora officinarum L.), ayahuasca (Banisteriopsis caapi Spruce ex Griseb.), and peyote 
(Lophophora williamsii (Lem.) Coult.), among others, experienced an important boom during 
the 1960s and 1970s (Shultes & Hofmann, 2008). This research work was oriented toward 
discovering and demonstrating certain pharmacological properties in these plant species. 
However, the fascinating success of these investigations was the Identification of very 
interesting chemical compounds that were useful as pharmacological tools for the study of 
the CNS (Tortoriello, 1999). From plant species, it has been possible to obtain chemical 
compounds that have been the basis of the development of chemical pharmaceuticals, such 
as reserpine, morphine, atropine, caffeine, and physostigmine (McClatchey et al., 2009). 
Over the past several years, in some countries and continuing to refer to Western medicine, 
phytopharmaceuticals products (containing plant extracts) have been developed. 
Phytopharmaceuticals, recognized in some countries as officially accepted drugs, are 
products in which identification of the active compounds has been reached and in which 
effectiveness, tolerability, and safety have been demonstrated by means of controlled clinical 
trials (Tortoriello et al., 2003). The following phytopharmaceuticals with CNS properties 
have been used broadly worldwide: Valeriana officinalis, prescribed principally for the 
treatment of insomnia (Salter & Brownie, 2010); Hypericum perforatum, the extract obtained 
from its roots is used for producing phytopharmaceuticals useful for treatment of mild to 
moderate depression (Kasper et al., 2010), and Ginkgo biloba, a widely recognized plant 
species due to its properties of improving cerebral blood flow and because of its effect on 
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memory disorders (Mashayekh et al., 2010). Regarding anxiety, it has not been easy to 
discover plant species with demonstrated selective activity without the evidencing of side 
effects. Piper methysticum G. Forster (Kava Kava) is a plant originally from Oceania 
(Polynesia, Micronesia, and Melanesia) from which a very important anxiolytic 
phytopharmaceutical was developed. Despite that the pharmacological mechanism of action 
has not been identified, pharmaceutical products elaborated from P. methysticum root extract 
were evaluated in clinical trials in which an anxiolytic effect, different from that produced 
by benzodiazepines, was demonstrated (Gastpar & Klimm, 2003). Different double-blind 
clinical studies compared the effects produced by P. methysticum against placebo in patients 
with a diagnosis of nonpsychogenic anxiety and in women with menopause-associated 
anxiety. The phytopharmaceuticals produced with this plant extract achieved wide 
commercial success in Europe and in some countries on the American Continent. However, 
due to reports of some cases of hepatotoxicity, pharmaceutical products elaborated with this 
extract were withdrawn from the market in different countries. Recent studies, performed 
after the warning report, have continued to evaluate this product therapeutically (vs. 
buspirone and opipramol), but several studies have had the purpose of evaluating the 
toxicological effects (Teschke et al., 2011). At present, P. methysticum is out of the formal 
ethics pharmaceutical market in the majority of countries.     
2. Ethnomedical use of Galphimia glauca in Mexican Traditional Medicine 
Galphimia glauca Cav., of the Malpighiaceae family, is a medicinal plant native to Mexico that 
is commonly known with the name of “Calderona amarilla” (Figure 1). Although there are 
no written documents, it has been known that from past times, this plant species has been 
employed in Mexican Traditional Medicine as a sedative and a tranquilizer for persons with 
insanity. The tranquilizing properties of this plant were also utilized during the “Cristeros” 
War (1926-1929) in Mexico; soldiers who had profuse diarrhea, severe paleness, and fear of 
going to battle received an infusion prepared with the leaves and stems of this plant, which 
afforded them great tranquility and the disappearance of nervous diarrhea.  
Galphimia glauca is a shrub that is widely distributed throughout Mexico due to its resistance 
to environmental conditions. Native to central Mexico, this evergreen plant has been known 
since pre-Columbian times. The Nahuatl people used the “totoncapatly” voice when 
referring to this shrub. Such an expression derives from the words “totonqui” and “patli”, 
which mean “hot” and “medicine”, respectively, in Nahuatl (Tortoriello, 1998).  
3. Preliminary pharmacological studies of G. glauca extracts on the CNS 
Based on the traditional medical use of this species, the methanolic extract of the aerial parts 
of the plant was evaluated in five neuropharmacological animal models. In all of these, the 
results obtained suggested a CNS depressor effect. The extract significantly potentiated the 
hypnotic effect induced by sodium pentobarbital in mice and reduced the effect of stimulant 
drugs administered in mice, such as strychnine and leptazol, producing in the animals an 
increment in the latency time of convulsions and diminishing the number of animals with 
convulsions, as well as mortality. Another depressor action was observed on the body 
temperature of the animals; administration in normothermic rats lowered the body 
temperature in a highly significant manner. On the other hand, it was demonstrated that G. 
glauca also depressed neuronal groups in in vitro isolated Guinea-pig ileum (Tortoriello & 
Lozoya, 1992).   
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Fig. 1. Galphimia glauca Cav. growing in a controlled crop. 
4. Chemical isolation and identification of the active compound 
By means of bioguided phytochemical separation, isolation was achieved of an active 
molecule whose structural elucidation demonstrated a nor-seco-triterpene. This compound 
is made up of 30 carbons organized in four rings with six members each, and a seventh 
member, hetero-cycle ring. Structurally, this compound comprises (4R)-Trihydroxy-13ǂ-
methoxycarbonyl-30-nor-3,4-seco-7ǂ,18ǃ-fridela-1,20-dien-3,24-olide, a new compound that 
received the trivial name of Galphimine-B or G-B (Figure 2). Chemical characterization was 
reached through exhaustive nuclear magnetic resonance (NMR) spectroscopic analysis of 1H 
and 13C, as well as x-ray diffraction of the crystallized compound (Toscano et al., 1993). 
Other compounds, with similar structures, have been isolated from the active extract. These 
compounds also present the six-ring structure with the seventh hetero-cycle member, but 
with different functional groups (Figure 2). All of these, known as Galphimines, have shown 
to possess less activity than G-B (González-Cortázar et al., 2005).  
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Fig. 2. Chemical structure of Galphimine- B (G-B), Galphimine-A (G-A), and Galphimine-E (G-E). 
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5. Anxiolytic effect and mechanism of action 
5.1 Anxiolytic effect of metanolic extract from Galphimia glauca 
In an assay carried out in ICR-strain male mice, it was demonstrated that the administration 
of increasing doses of the methanolic extract of Galphimia glauca (125, 250, 500, 1,000, and 
2,000 mg/kg via oral route) caused a significant increase in animals in terms of the 
percentage of time that the mice remained on the open arms of the elevated plus maze  
(EPM), as well as also an increase in the percentage of number of crossings that the mice 
carried out toward these arms (p <0.05) (Figure 3). The data were compared with the group 
that only received a Tween 20 solution at 5% (vehicle, 10 l/10 g of the weight of the 
mouse). The G. glauca extract utilized in this model was standardized in its G-B content, 
establishing that it contained 8.3 mg G-B/g of extract. As described in the literature (Rex et 
al., 2002), diazepam at 1.0 mg/kg was capable of inducing a significant increase in 
comparison with the control group (p <0.05) in the parameters previously cited, this 
indicative of pharmacological model validation (Herrera-Ruiz et al., 2006A). 
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Fig. 3. Effect produced by different doses of methanolic extract from Galphimia glauca on ICR 
mice exposed to the elevated plus maze paradigm. *P <0.05 with ANOVA followed by post-
hoc Dunnett test (mean ± Standard deviation [SD]; n = 7). DZP = diazepam; VEH = Vehicle 
(solution of Tween 20 at 5%). %EOA = mean percentage of the number entries on the open 
arms of the EPM; % TOA = mean percentage of time spent on the open arms of the EPM.  
It has been proposed that adequate interpretation of the results in the EPM should be 
accompanied by an analysis of the ethological parameters that improve the model’s 
sensitivity and that allow for identification of the emotional changes in the animals (Cole  
Rodgers, 1994). These parameters can be confounder factors predicting the anxiolytic 
capacity of the treatments. In this way, it is suggested that within the EPM, it would be 
necessary to analyze the ethological measurements of Head dips (HD) (Weiss et al., 1998). 
Thus, for example, the increase in the number of HD on open arms is a behavior that is 
inversely correlated with the level of anxiety. This means that the more HD performed by 
the animals, the less anxiety demonstrated; this is a risk appraisal parameter, and this 
behavior is reported for substances such as diazepam (Cruz et al., 1994; Rodgers  Johnson, 
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1995). In the case of the administration of the methanolic extract of G. glauca, the number of 
HD was significantly greater (p <0.05) than that of the group that only received the vehicle; 
this parameter increased in a dose-dependent manner (Table 1). On the other hand, similar 
behavior was observed in the group of animals that received benzodiazepine . 
Vertical exploration, or Rearings (R) is commonly accepted as a measurement of locomotor 
activity (Ramos et al., 1997). A decrease in the number of R can be related with the reduction 
in crossings to closed arms, where this behavior regularly occurs. It has been observed that 
diazepam causes a diminution in mice of the number of R, thus associating this with a 
diminution in the number of entrances on the closed arms. This behavior is in agreement 
with the results obtained with the increasing administration of the standardized G. glauca 
extract and also with diazepam; both treatments induce a significant diminution of R with 
respect to the vehicle (p <0.05) (Table 1). 
In addition to the effect observed in the EPM model, we also evaluated the standardized 
extract of G. glauca (different doses) on the Light/dark model; this is a paradigm based on 
the rejection of rodents to travel through the brilliantly illuminated areas and on their 
spontaneous exploratory behavior in the face of the novelty of the environment (Crawley  
Goodwing, 1980). It has been determined that this test is useful in predicting the anxiolytic 
or anxiogenic capacity of different treatments. Benzodiazepines and serotonergic drugs can 
be detected as anxiolytics employing the Light-dark methodology (Hascoët et al., 2001).  
 
Treatment doses HD R 
G. glauca 125 29.3 ± 6.6* 14.5 ± 2.5* 
G. glauca 250 29.5 ± 3.6* 13.3 ± 1.8* 
G. glauca 500 34.4 ± 7.1* 15.1 ± 2.9* 
G. glauca 1,000 35.1 ± 7.9* 12.8 ± 3.7* 
G. glauca 2,000 39.1 ± 6.3* 10.4 ± 4.8* 
DZP 1.0 51.0 ± 12.0* 13.4 ± 2.1* 
VEH (10 µl/10 g) 13.7 ± 3.3 23.6 ± 2.8 
Data presented as means ± Standard error of mean [SEM] with n = 7, *p <0.05 compared with control 
using Analysis of variance (ANOVA) and post-hoc Dunnett test. HD = Head-dips; R = Rearings. 
Table 1. Ethological parameters recorded in the Elevated plus maze (EPM) with different 
doses (mg/kg) of the methanolic extract from Galphimia glauca  
In this model, the different dosages of the standardized extract of G. glauca induced a 
significant increase in the time that the mice spent in the illuminated compartment, thus 
indicative of an anxiolytic effect; the data obtained with this treatment were similar to those 
yielded by the group of mice who received diazepam at 1.0 mg/kg (Figure 4).  
With the models of the EPM and the Light/dark compartment, it was able to be 
demonstrated that the standardized G. glauca extract possesses an anxiolytic effect in the 
pre-clinical experimentation phase. 
5.2 Anxiolytic effect produced by the isolated Galphimines 
From the active extract of Galphimia glauca, we obtained samples of pure Galphimines. The 
authenticity of the G-B, G-A, and G-E compounds were confirmed by NMR spectroscopy 
tests of 1H and 13C. We also included, for comparative purposes, a sample that contained the 
three Galphimines together: G-B, G-A, and G-E, but without other compounds of the whole 
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extract (fraction of Galphimines, GRF). Intraperitoneal (i.p.) administration of G-B, G-A, and 
the GRF at a dose of 15 mg/kg produced, in male mice, a significant increase in the 
percentage of time that the animals spent on the open arms and percentage of number of 
crossings in these arms; this behavior was similar to that observed in the group that received 
diazepam at 1.0 mg/kg, but significantly different from that of the group that received the 
vehicle (10 µl/10 g of weight of Tween 20 solution at 5%) (p <0.05) (Figure 5) (Herrera-Ruiz 
et al., 2006B).   
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Fig. 4. Effect produced by different doses of the methanolic extract from Galphimia glauca on 
the time spent by ICR mice in the illuminated compartment in the Light-dark test. *p <0.05 
with Analysis of variance (ANOVA) followed by post-hoc Dunnett test (mean ± Standard 
deviation [SD]; n = 7). DZP = diazepam; VEH = Vehicle (solution of Tween 20 at 5%). 
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Fig. 5. Effect produced by G-B, G-A, and the pool of Galphimines on ICR mice exposed to 
the elevated plus-maze paradigm. *P <0.05 with Analysis of variance (ANOVA) followed by 
post-hoc Dunnett test (mean ± Standard deviation [SD]; n = 7). DZP = diazepam; VEH = 
Vehicle (solution of Tween 20 at 5%). 
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The ethological parameters associated with the evaluation of the number of crossings and 
the percentage of time on open arms was also registered for this assay. As can be observed 
in Table 2,  the number of HD is significantly greater for animals treated with G-B, G-A, the 
GRF, and diazepam when statistically compared with the control (p <0.05). In agreement 
with these data, we observed a statistically different diminution in the R parameter for all 
anxiolytic treatments in comparison with the vehicle (p <0.05) (Table 2). 
 
TX/doses Head dips Rearings 
G-B 15 45.5 ± 12.32* 6.3 ± 2.34* 
G-A 15 33.2 ± 7.31* 13.3 ± 2.94* 
Pool 15 37.2 ± 7.56* 9.2 ± 3.8* 
DZP 1.0 44.1 ± 10.49* 9.62 ± 4.1* 
VEH (10 µl/10 g) 25.6 ± 4.53 22.2 ± 6.9 
Data presented as means ± Standard error of mean [SEM] with n = 7; *P <0.05 compared with control 
using Analysis of variance (ANOVA) and post-hoc Dunnett test. 
Table 2. Ethological parameters recorded in the Elevated plus maze (EPM) with different 
Galphimines (mg/kg) from Galphimia glauca 
The data accumulated on the anxiolytic activity of the standardized extract of G. glauca  and 
its triterpenic derivatives show that this Mexican medicinal species possesses effects of 
central depression, whose action on animal models induces behavior similar to that of 
substances that are clinically utilized as main therapeutic resources for treating illnesses 
such as anxiety, as is the case of benzodiazepines.  
5.3 Action mechanism of G-B 
Pure G-B has been evaluated in different pharmacological tests. These results showed that 
this compound, administered i.p. in mice, did not exhibit any significant effect as an 
anticonvulsant; however, it was able to increase significantly the hypnotic effect induced by 
sodium pentobarbital on mice in a dose-dependent manner. This compound also produced 
strong inhibition of the electrically-induced contraction of Guinea-pig ileum (Tortoriello  
Ortega, 1993). These results suggested that the effect produced by G-B is not manifested in 
generalized motor processes, for example, in protection against induction of convulsion in 
mice. However, the pharmacological effect is observed in motor activities directed toward 
an objective as a goal, such as occurs with stereotypic-activity localization and adaptation in 
novel environments or in specific behaviors such as hypnosis induction in mice. These data 
supported, from that time, the idea of a selective action mechanism, particularly on regions 
that regulate motivational behaviors that are implicated in the processes of punishment and 
reward with a strong motor component. With these bases, the interaction of G-B with some 
of the cerebral stem structures was explored. Receptor binding experiments did not 
demonstrate any affinity of G-B with clonazepam, diazepam, or opioid receptors. 
Unexpectedly, extracellular unitary neuronal records in whole animals showed that G-B 
modified, with specificity, the electrical activity of ventral tegmental area (VTA) neurons in 
rats (Tortoriello et al., 1998). It was also observed that the inhibitory effect produced by G-B 
on the frequency of discharge takes place only in neurons with specific discharge patterns. 
The effect was observed on neurons with low frequency with periodic and rhythmic burst 
discharges, compatible with dopaminergic neurons. In general, G-B inhibits the activity of 
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the mesencephalic dopaminergic pathways. Intracellular records in brain slices showed that 
G-B inhibits the excitatory postsynaptic potentials; this effect was similar to that produced 
by GABA and clonazepam (Prieto Gómez, et al., 2003). Nonetheless, the effect produced by 
G-B was not blocked by bicuculline, picrotoxin, or flumazenil, thus providing an action 
mechanism independent of the GABA-A receptor.         
6. Evaluation of the toxic activity of extracts obtained from Galphimia glauca 
The safety of the G. glauca anxiolytic extract has been evaluated in pre-clinical toxicology 
assays using rodents under a chronic administration scheme. Determination of the possible 
toxic effects of this medicinal species was conducted with different extracts with the purpose 
of conciliating, on the one hand, the greatest efficacy of the extract with the least number of 
side effects, or, in the best of cases, the absence of the latter (Aguilar-Santamaría et al., 2007).  
After oral administration of the 2.5 g/kg dose of the aqueous, methanolic, and ethanolic 
extracts of G. glauca in a 28-day daily scheme to Balb-C mice of both genders, it was 
performed an evaluation on the liver, due to that administration via oral route ensures the 
passage of this phytopharmaceuticals through this organ by means of the portal circulation. 
Based on the anatomic position between the gastrointestinal tract and systemic circulation, 
the liver plays an important role in the metabolism of exogenous substances (Grosse-
Siestrup et al., 2002). The hepatotoxic effects produce tissue alterations accompanied by the 
liberation of the cellular contents into the plasma, such as the Alanine aminotransferase 
enzyme (ALT), the Aspartate aminotransferase enzime (AST), and the Alkaline phosphatase 
enzyme (ALP), which takes place after an acute inflammatory process and which is 
eventually related with the oxide-reduction equilibrium of the hepatocytes (Stirnimann et 
al., 2010). The results of the serum analysis of these enzymes, in the different groups of mice 
with the extracts administered, show that there are no changes in the activity of these with 
respect to the control group, which suggests a lack of liver damage (Figure 6). 
As a complementary analysis, it is important to evaluate the neurotoxicological component 
by means of the observation of the Animal´s behavior. For this, it was daily observed the 
behavior and the physiological state of the mice, initially described by Samuel Irwin (Irwin, 
1968). With this method, it was evaluated consciousness, mood state, motor activity, CNS 
excitation, posture, motor coordination, muscular tone, reflexes, and autonomic competence. 
Chronic administration of the extracts of G. glauca caused changes in the behavior of the 
mice. In special fashion, the methanolic extract produced piloerection, loss of equilibrium, 
and diminution in the straightening reflex, without modification of other signs, such as 
tearing, modification of the diameter of the pupil, respiratory movements, paralysis, and 
diminution of prehensile activity. Dehydration was also observed, as a consequence of 
treatment, which can be associated with a possible non-quantified diuretic effect, while it 
cannot be associated with diarrheic evacuations. These changes can be due to a potent 
depressor effect of the CNS produced by the prolonged administration time of the extracts 
at doses as high as 2.5 g/kg (Aguilar-Santamaría et al., 2007).  
The therapeutic safety of the extracts of Galphimia glauca was also analyzed through the 
cytotoxicity technique on cell lines cultured in vitro as follows: colon cancer (HCT-15); uterine 
cervix cancer (UISO); human nasopharyngeal cancer (KB), and ovarian cancer (OVACAR-5). 
Determination of the cytotoxic effect was based on quantification of the concentration of 
proteins at the end of treatment (Oyama & Tagle, 1956), and results were expressed as the 
concentration that inhibited 50% of growth of the control treatment (EC50). Values were 
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estimated on the semi-log graph of the concentration of the extract (µg/ml) vs. the percentage 
of viable cells. The data indicated that the three extracts from Galphimia glauca did not induce 
cytotoxicity on the cell lines derived from nasopharyngeal tissue (KB), uterus (UISO), and 
ovary (OVCAR-5), in which the EC50 was <2 µg/ml. The cytotoxic effect was only apparent 
with the colon line (HCT-15), in which ED50 values were 0.63, 0.50, and 1.99 µg/ml for the 
ethanolic, methanolic, and aqueous extracts, respectively (Aguilar-Santamaría et al., 2007). 
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Fig. 6. Enzymatic activities in serum of Alkaline phosphatase (ALP, panel A), Alanine 
aminotransferase (ALT, panel B), and Aspartate aminotransferase (AST, panel C) of mice 
exposed for 56 days to the ethanolic, methanolic, and aqueous extracts of Galphimia glauca. 
The results are expressed as means  Standard deviation (SD); analysis was carried out by 
means of Analysis of variance (ANOVA) and the Bonferroni post-test. Statistical significance 
was p <0.05. 
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Another safety parameter was evaluated by means of the genotoxicity technique in the 
peripheral lymphocytes of healthy volunteers; the cells were cultured with increasing 
concentrations of G. glauca extracts and the results were compared with the negative (saline 
solution at 0.9%) and the positive control (cyclophosphamide, 0.025 µl/ml). The culture was 
maintained for 72 h under standard maintenance conditions; at the end, a smear was carried 
out that stained with Wright stain  and these were observed under the microscope (Perry & 
Wolf, 1974) in order to observe the sister chromatids and the presence of micronuclei; 10,000 
lymphocytes were evaluated under the optical microscope with criteria defined by Fenech 
(2000). The data indicate that under this design, none of the extracts caused a genotoxic 
effect (Aguilar-Santamaría et al., 2007). 
The content of Galphamines was quantified in each of the three extracts (Table 3).  
 
Extract Compound Concentration (mg/g) 
Aqueous 
G-A 0.6 
G-B 1.034 
G-E 1.12 
Methanolic 
G-A 7.29 
G-B 17.47 
G-E 13.6 
Ethanolic 
G-A 5.35 
G-B 18.8 
G-E 17.49 
Table 3. Galphmine content, extraction yield, and chromatographic analysis in High 
performance liquid chromatography (HPLC) of the different Galphimia glauca extracts 
7. Effectiveness and tolerability of a phytopharmaceutical containing the 
standardized extract of G. glauca on patients with generalized anxiety 
disease  
Based on the findings of the anxiolytic pharmacological activity of the plant species 
Galphimia glauca, and with the intention to propose a new alternative for the treatment of the 
generalized anxiety disorder (GAD), a phytopharmaceutical was generated from a dry 
extract from the aerial parts of this plant species, standardized in its G-B content (active 
compound). In this manner, to initiate the systematic study of the novel 
phytopharmaceutical, it was proposed the generation of clinical evidence on its safety and 
therapeutic effectiveness in patients with GAD, comparing it against a widely used drug 
belonging to the group of benzodiazepines (Herrera-Arellano et al., 2007). 
The raw material or plant drug was obtained from a controlled culture generated by means 
of micropropagation in an experimental field localized in Xochitepec, Morelos, Mexico. The 
culture was supervised in accordance with good agricultural practices (OMS, 2003). A 
sample was identified by Abigail Aguilar–Contreras, M.Sc., and deposited in the Medicinal 
Herbarium of the IMSSM as reference. The plant raw material, leaves and stems, was dried 
under conditions of darkness, at room temperature, for a 2-week period; later, this was 
triturated and ground until we obtained 1-3-mm particles, which were stored in 
hermetically sealed containers until use. 
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The extract that was employed to formulate the phytopharmaceutical was obtained by 
maceration in water at 60º C for 2 h. The liquid extract was dried in two phase: the first, by 
distillation at reduced pressure (Heidolph, Laborota 20), and later, by a spray-dry system. 
The dry extract was collected and stored at 4ºC until formulation of the 
phytopharmaceutical. Chromatographic analysis by HPLC of the extract indicated that the 
drying system did not modify the concentration of G-B. The final yield of the extraction 
process was 5%, and each g of the extract contained 1.12 mg of G-B.   
The experimental treatment corresponding to the G. glauca pharmaceutical was formulated 
in hard gelatin capsules. Each capsule contained 310 mg of dry extract, at least 0.350 mg of 
G-B/capsule, and 500 mg of vehicle; the capsules were packed individually in blister packs 
of 10 units each. Several methodologies on the previously lacked drug for quality control 
were carried out, based on Official Mexican Norms: NOM-059-SSA1-1993 and NOM-073-
SSA1-1993. Additionally, the analyses were conducted according to the Pharmacopoeia of 
the United Mexican States [2004]. The control treatment was formulated with 1.0 mg de 
lorazepam, with the same pharmaceutical presentation, packaging, and quality as the 
experimental drug. 
7.1 Description of the clinical study  
With the authorization of and registry number 2003-322-0010 of the Mexican Institute of 
Social Security (IMSS) Ethics and Research Committee, adult, ambulatory males and females 
between the ages of 18 and 65 years where included in the study.  Patients must reunite the 
DSM IV diagnostic criteria for GAD, and a Hamilton (HAM-A) scale score ≥19 points, 
without pharmacological treatment in the month prior to their inclusion. In addition, the 
subjects could not present a history of current use, for at least 6 months previously, alcohol 
or drug addiction or abuse, nor data of suicidal ideation or of another psychiatric pathology 
that was clinically more relevant than GAD, and the signing of a letter of informed consent 
Clinical, randomized, double-blind and controlled study was carried out at the Hospital 
General of the IMSS in Cuernavaca, Morelos, Mexico. The experimental group was treated 
with capsules containing the aqueous and the dry extract of G. glauca (standardized in 0.350 
mg of G-B) at a dose of one capsule every 12 h for 4 continuous weeks. The control group 
received 1.0 mg of lorazepam at the same dose. The main outcome variable, therapeutic 
effectiveness, was considered when the HAM-A scale score was <18 points. Secondary 
variables included tolerability (the absence of intense or severe sedation, which merited 
treatment suspension) and therapeutic safety (at the end of the study, the absence of 
pathological alterations in the biochemical tests of hepatic and renal function: ALT; AST, 
serum urea, and serum creatinine). In addition, from week 1 of treatment, we implemented 
two scales to appraise the therapeutic effect of the treatment assigned by means of the scales 
denominated Global patient evaluation (GPE) and Global clinical impression (GCI). Patients 
were scheduled weekly on four occasions to evaluate the proposed outcomes, the presence 
of side effects (through a scale designed ad hoc, composed of 50 and additional items that 
evaluated the severity of these), treatment compliance (ingestion of at least 80% of the 
prescribed doses), and resupply of the assigned drug. 
To evidence the differences among treatments, the Analysis of variance (ANOVA) test was 
utilized, a reliable statistical method for comparing continuous variables with normal 
distribution, while the non-parametric Wilcoxon and Mann-Whitney U tests were employed 
for comparing paired and independent data, respectively. The X2 test served for comparing 
two proportions; p values ≤ 0.05 were considered as a significant difference.  
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7.2 Results of the clinical study in patients with GAD 
The study began with 152 patients (72 in the experimental group). Table 4 compares the 
population characteristics on initiation of the clinical assay; significant differences were not 
appreciated in any of the parameters evaluated (p ≥0.17). It is noteworthy that on beginning 
the study, the average patients age was 37.8 years, with 4.1 years of GAD disease evolution 
and 29 points on the HAM-A scale; in addition, feminine gender predominated with 
schooling equal to or greater than high school.  
 
Variable G. glauca (n = 72) Lorazepam (n = 80) ANOVA 
 m SD m SD P 
Age (years) 38.38 11.13 37.35 11.49 0.57 
Weight (kg) 66.08 12.34 67.64 13.05 0.45 
Height (cm) 158.33 9.75 157.83 7.72 0.72 
BMI (kg/m2) 26.38 4.42 27.16 4.99 0.31 
SBP (mmHg) 114.58 10.99 114.59 10.050 0.96 
DBP (mmHg) 72.62 9.90 72.31 9.34 0.84 
CF (beats/min) 79.79 4.86 79.31 7.39 0.64 
RF (resp/min) 20.98 1.975 20.96 1.99 0.94 
GAD evolution 
(months) 
51.18 56.01 48.35 59.91 0.76 
 F % F % X2  p 
Gender     0.58 
Masculine 18 25.00 17 21.25  
Feminine 54 75.00 63 78.75  
School grade reached     0.66 
≤Elementary 34 47.22 35 43.75  
≥High school 38 52.78 45 56.25  
Occupation     0.88 
Homemaker 26 36.11 28 35.00  
Other 46 63.89 52 65.00  
Comorbidity     0.59 
Positive 24 33.33 30 37.50  
Negative 48 66.67 50 62.50  
Smoking     0.98 
Positive 17 23.61 19 23.75  
Negative 55 76.39 61 76.25  
Previous alcoholism     0.17 
Positive 16 22.22 11 13.75  
Negative 56 77.78 69 86.25  
Previous drug addiction     0.89 
Positive 5 6.94 6 7.50  
Negative 67 93.06 74 92.50  
ANOVA = Analysis of variance; BMI = Body mass index; SBP = Systolic blood pressure; DBP = Diastolic 
blood pressure; CF = Cardiac frequency; RF = Respiratory frequency; GAD = Generalized anxiety disease. 
Table 4. Comparison of the population characteristics on study initiation. Values correspond to 
means (m) and Standard deviation (SD), absolute frequencies (f), and relative frequencies (%) 
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During the development of the clinical assay, 38 subjects were excluded, the majority 
belonging to the lorazepam-treated group (21, 55.26%). Incapacitating sedation was the 
main reason for exclusion; this presented in 20 patients, of among whom four belonged to 
the group treated with the G. glauca phytopharmaceutical. The remaining 18 subjects were 
excluded due to non-drug-related reasons 
For the therapeutic effectiveness analysis, 114 patients, who concluded the entire study, 
were included. For analyzing tolerability, 20 subjects who were excluded due to 
incapacitating morning sedation were added. Finally, in the therapeutic safety analysis, 113 
patients who concluded the study were included, with the exception of one patient who did 
not allow a final blood sample to be performed for the programmed biochemical studies.  
the therapeutic tolerability analysis, evaluated as morning sedation, exhibited significant 
differences in favor of the phytopharmaceutical (6.78 vs. 21.33%; X2, p = 0.01), while none of 
the patients on whom we practiced the programmed laboratory tests showed pathological 
results;  therapeutic safety was 100% in both groups.  
Therapeutic effectiveness was evaluated mainly by means of the HAM-A scale, which was 
complemented with the EGP and the GCI. It is noteworthy that at the end of the study, both 
treatments significantly reduced these three scales (Wilcoxon, p ≤0.0001). In Figure 7, it may 
be observed that the two treatments diminished with regard to the HAM-A scale from week 
1 and during the subsequent 3 weeks in similar fashion (Mann-Whitney, p >0.54). Likewise, 
on concluding the study, there were no significant differences among treatments with this 
scale. It is noteworthy that the phytopharmaceutical diminished HAM-A from 29 to 9 points 
(65.62%). In addition, at the end of the study, the phytopharmaceutical from G. glauca 
obtained 80% anxiolytic effectiveness, while lorazepam obtained 81.3%. 
Figures 8 and 9 compare the effect produced by both treatments in terms of the GCI and 
EGP scales. It is possible to appreciate that in this analysis, the phytopharmaceutical 
achieved a better score with both scales, principally in weeks 2 and 3 of administration.  
However, the differences were not significant (Mann-Whitney U, p >0.09), It is noteworthy 
that the phytopharmaceutical diminished the IGC from 8 to 4 points and the EGP, from 9 to 
4 points.   
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Fig. 7. The figure shows the effect of the treatments administered during 4 weeks on the 
Hamilton anxiety scale. Values correspond to means and Standard Error (SE) (Mann-
Whitney U, p ≥0.54). 
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Fig. 8. Figure that shows the effect of treatments administered during 4 weeks on the global 
clinical impression (GCI) scale. Values correspond to means and Standard error (SE) (Mann-
Whitney U, p ≥0.09) 
 
 
Fig. 9. Figure than shows the effect of the treatments administered during 4 weeks on the 
global patient evaluation (GPE) scale. Values correspond to means and Standard error (SE)  
(Mann-Whitney U, p ≥0.37). 
The stratified analysis, useful to appraise the effect of some confounders on the therapeutic 
effectiveness of the phytopharmaceutical of G. glauca, demonstrated that the gender of the 
subject, the subject’s weight, and the disease evolution time did not fall into the anxiolytic 
effect (p ≥0.55); however, age and the basal score on the HAM-A scale did exert an influence 
on the outcome, because subjects >38 years or with HAM-A ≤30 points showed greater 
percentages of therapeutic effectiveness (p ≤0.03). 
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8. Conclusion 
An innovative anxiolytic phytopharmaceutical has been developed by means of an 
interdisciplinary work. This product exhibited an innovative mechanism of action through 
an interaction with the dopaminergic system in CNS. This product was evaluated clinically 
by means of a double-blind clinical trial in order to compare it with lorazepam (1 mg, twice 
daily) in terms of therapeutic effectiveness, safety, and tolerability in patients with 
Generalized anxiety disorder (GAD). After 4 weeks of treatment, the phytopharmaceutical 
showed important anxiolytic effectiveness, very similar to that produced with lorazepam. 
However, regarding side effects, the phytopharmaceutical evidenced considerably higher 
tolerability than lorazepam.  
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